Therese Granström1, Henrietta Forsman2, Anna Lindholm Olinder3, Dimitrios Gkretsis4, Jan W Eriksson5, Elisabet Granstam6, Janeth Leksell7. 1. School of Education, Health and Social Studies, Dalarna University, Falun, Sweden; Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Electronic address: tga@du.se. 2. School of Education, Health and Social Studies, Dalarna University, Falun, Sweden. Electronic address: hfo@du.se. 3. Department of Medical Sciences, Uppsala University, Uppsala, Sweden; Sachs Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden; Department of Clinical Research and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden. Electronic address: anna.lindholm_olinder@medsci.uu.se. 4. Department of Ophthalmology, Dalarna County Hospital, Falun, Sweden. Electronic address: dimitrios.gkretsis@ltdalarna.se. 5. Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Electronic address: jan.eriksson@medsci.uu.se. 6. Center for Clinical Research Västmanland County Hospital, Uppsala University/County Council of Västmanland, Västerås, Sweden; Department of Ophthalmology, Västmanland County Hospital, Västerås, Sweden. Electronic address: elisabet.granstam@ltv.se. 7. School of Education, Health and Social Studies, Dalarna University, Falun, Sweden; Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Electronic address: jle@du.se.
Abstract
AIMS: To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), patient reported outcome and describe levels of glycated hemoglobin and its association with the effects on visual acuity in patients treated with anti-VEGF for visual impairment due to diabetic macular edema (DME) during 12months in a real world setting. METHODS: In this cross-sectional study, 58 patients (29 females and 29 males; mean age, 68years) with type 1 and type 2 diabetes diagnosed with DME were included. Medical data and two questionnaires were collected; an eye-specific (NEI VFQ-25) and a generic health-related quality of life questionnaire (SF-36) were used. RESULTS: The total patient group had significantly improved visual acuity and reduced retinal thickness at 4months and remains at 12months follow up. Thirty patients had significantly improved visual acuity, and 27 patients had no improved visual acuity at 12months. The patients with improved visual acuity had significantly improved scores for NEI VFQ-25 subscales including general health, general vision, near activities, distance activities, and composite score, but no significant changes in scores were found in the group without improvements in visual acuity. CONCLUSIONS: Our study revealed that anti-VEGF treatment improved visual acuity and central retinal thickness as well as patient-reported outcome in real world 12months after treatment start.
AIMS: To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), patient reported outcome and describe levels of glycated hemoglobin and its association with the effects on visual acuity in patients treated with anti-VEGF for visual impairment due to diabetic macular edema (DME) during 12months in a real world setting. METHODS: In this cross-sectional study, 58 patients (29 females and 29 males; mean age, 68years) with type 1 and type 2 diabetes diagnosed with DME were included. Medical data and two questionnaires were collected; an eye-specific (NEI VFQ-25) and a generic health-related quality of life questionnaire (SF-36) were used. RESULTS: The total patient group had significantly improved visual acuity and reduced retinal thickness at 4months and remains at 12months follow up. Thirty patients had significantly improved visual acuity, and 27 patients had no improved visual acuity at 12months. The patients with improved visual acuity had significantly improved scores for NEI VFQ-25 subscales including general health, general vision, near activities, distance activities, and composite score, but no significant changes in scores were found in the group without improvements in visual acuity. CONCLUSIONS: Our study revealed that anti-VEGF treatment improved visual acuity and central retinal thickness as well as patient-reported outcome in real world 12months after treatment start.
Authors: Krystal Khoo; Ryan E K Man; Gwyn Rees; Preeti Gupta; Ecosse L Lamoureux; Eva K Fenwick Journal: Qual Life Res Date: 2019-03-16 Impact factor: 4.147
Authors: Nakhleh E Abu-Yaghi; Alaa M Abed; Dana F Khlaifat; Mohammed B Nawaiseh; Laith O Emoush; Heba Z AlHajjaj; Ala M Abojaradeh; Mariana N Hattar; Sura K Abusaleem; Hashem M Sabbagh; Yazan A Abu Gharbieh; Sura A Quaqazeh Journal: Clin Ophthalmol Date: 2020-03-24
Authors: Christoph Kern; Johannes Schiefelbein; Dun Jack Fu; Benedikt Schworm; Dawn Sim; Tina Herold; Siegfried Priglinger; Karsten Kortuem Journal: Clin Ophthalmol Date: 2020-02-26